Here's a podcast from the webinar presentation earlier this month by our beloved Dr. Weiss, covering the open question of whether we should consider giving an EGFR inhibitor like Tarceva (erlotinib) as an adjuvant (post-operative) therapy following potentially curative surgery for early stage NSCLC. It's a setting in which there is a good rationale if we extrapolate from the setting of metastatic NSCLC, at least for patients with an EGFR mutation, but we've made incorrect presumptions before when we extrapolate.

Dr. Weiss reviews the pros and cons and the scant relevant data in his podcast. Below you'll find the audio and video versions of his presentation with Q&A that followed, as well as the figures and transcripts that go with this.

[powerpress]

weiss-adjuvant-egfr-tki-webinar-audio-podcast

weiss-adjuvant-egfr-tki-webinar-figures

weiss-adjuvant-egfr-tki-webinar-transcript

And for those of you asking about the most recent webinars, by Drs. Ramalingam and Socinski, we're targeting getting those up for everyone by next week.